Updated:
Champions Oncology
Champions Oncology built its business on a proprietary bank of patient-derived xenograft (PDX) tumor models, implanting human cancer tissue into mice to...
Champions Oncology
Champions Oncology built its business on a proprietary bank of patient-derived xenograft (PDX) tumor models, implanting human cancer tissue into mice to preserve biological characteristics for drug testing. The company sells this service to pharma and biotech clients seeking predictive preclinical data before committing to expensive human trials. The core economic engine is not a transactional CRO fee but a recurring, platform-based model where clients license models, run multi-arm studies, and return for comparative analyses. The strategy centers entirely on oncology, spanning target validation, compound screening, and biomarker discovery. Published case studies reference work with major global pharma companies on programs covering immunotherapies, targeted small molecules, and antibody-drug conjugates. Geographic coverage includes the U.S., Europe, and Asia-Pacific markets, with a lab footprint in New Jersey serving as the operational hub. Champions Oncology operates as a publicly traded company (NASDAQ: CSBR) with a market capitalization historically in the low hundreds of millions. The firm has no disclosed separate asset management vehicle, but its business model — licensing a proprietary physical asset library (tumor tissue) alongside computational analysis — creates a recurring-revenue structure unusual in preclinical services. Structurally, the company differs from a standard preclinical CRO because the value derives from the exclusivity and predictive power of its tumor bank, which competitors cannot easily replicate. This creates a narrow but defensible moat in a specific, high-stakes segment of the oncology drug development pipeline.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Hackensack
Corporate office
Hackensack, NJ, United States
Sector focus
Frequently asked questions
What is Champions Oncology's core business?
Champions Oncology provides preclinical oncology research services using patient-derived xenograft (PDX) models. The company implants human tumor tissue into mice to create models that more accurately predict drug response in clinical trials. Pharmaceutical and biotechnology companies use these models for drug development, target validation, and biomarker discovery. The company is publicly traded under the ticker CSBR.
How does the PDX platform generate revenue?
Revenue comes from licensing the proprietary PDX tumor model library and performing preclinical studies for pharmaceutical and biotech clients. The model creates a recurring revenue stream as clients often return for additional studies, comparative analyses, and new model access. This contrasts with one-off contract research organization (CRO) project work.
Which therapeutic areas does Champions Oncology cover?
The company focuses exclusively on oncology, the treatment of cancer. Its platform supports development across immunotherapies, targeted therapies, chemotherapies, and antibody-drug conjugates. The tumor model bank covers a wide range of cancer subtypes, reflecting the broader oncology drug development landscape.
Is Champions Oncology a CRO?
Functionally, it operates in the preclinical CRO space, but its structural model differs from standard CROs. The value proposition centers on a proprietary, exclusive physical asset — a bank of patient-derived tumor models — rather than just labor and protocol execution. This gives the company a defensible position that pure-play CROs lack.
Does Champions Oncology manage external capital?
No. Champions Oncology does not manage third-party capital or operate as a family office or investment fund. It is an operating company that provides services to the biopharmaceutical industry, funded by its balance sheet and public equity as a NASDAQ-listed company.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: